Possible Collateral Estoppel in OxyContin Case Due to This Month’s Teva Decision

Purdue Pharma L.P. et al. V. Mylan Pharmaceuticals Inc. et al.

Case Number: 1:12-cv-02959-SHS (Dkt. 44)

In light of the court’s Findings of Fact and Conclusions of Law in related matters (Dkt. 634) that held certain claims of U.S. Patents Nos. 7,674,799 (entitled “Oxycodone hydrochloride having less than 25 ppm 14–hydroxycodeinone”), 7,674,800 (same), and 7,683,072 (same) to be invalid, Judge Stein ordered Purdue to show cause why plaintiffs should not be collaterally estopped from asserting those claims in the instant matter.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.